Lisa M. Rimsza

Dr. Lisa M. Rimsza


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2004 in Blood
Verified
Journal Article
Closed access
PDF file
LRLisa M. Rimsza
Lisa M. Rimsza
RRRobin A. Roberts
Robin A. Roberts
TMThomas P. Miller
Thomas P. Miller
JUJoseph M. Unger
Joseph M. Unger
MLMichael LeBlanc
Michael LeBlanc
TGThomas M. Grogan
Thomas M. Grogan
The Leukemia and Lymphoma Molecular Profiling Project recently published results from DNA microarray analyses of 240 diffuse large B-cell lymphomas (DLBCLs). Four gene expression “signatures” were identified as correlated with patient outcome, including the major histocompatibility complex (MHC) class II genes (eg, HLA-DRA) which correlated with better survival. We further analyzed the effects of HLA-DRA on survival and correlated gene expression with protein status and tumor-infiltrating lymphocytes. The 5-year overall survival was 24% in the lowest 10% of HLA-DRA expression, 37% in the 10% to 25% group, 50% in the 25% to 50% group, and 55% for patients in the highest 50%. Further analysis demonstrated that the hazard ratio of death was a nonlinear function of HLA-DRA expression. Adjustment for the International Prognostic Index did not alter the impact of HLA-DRA on survival. Other MHC class II genes were found to predict survival similarly. Microarray HLA-DRA expression correlated with the presence or absence of human leukocyte antigen-DR (HLA-DR) protein in 20 of 22 cases assessed. Fewer tumor-infiltrating CD8+ T cells were detected in MHC class II-negative cases compared with positive cases (2.8% versus 11.0%; P = .001), supporting the hypothesis that loss of tumor immunosurveillance has a devastating effect on patient outcome in DLBCL. (Blood. 2004; 103:4251-4258)

1 July 2006 in Blood
Verified
Journal Article
Closed access
PDF file
RRRobin A. Roberts
Robin A. Roberts
GWGeorge Wright
George Wright
ARAndreas R. Rosenwald
Andreas R. Rosenwald
MJMarina A. Jaramillo
Marina A. Jaramillo
TGThomas M. Grogan
Thomas M. Grogan
LRLisa M. Rimsza
Lisa M. Rimsza
Loss of major histocompatibility class II (MHC II) expression in diffuse large B-cell lymphoma (DLBCL) correlates with worse outcome, possibly from decreased immunosurveillance. Primary mediastinal B-cell lymphoma (PMBCL) is a subtype of DLBCL which reportedly has frequent loss of MHC II proteins; however, PM-BCL has better survival than DLBCL. To investigate this paradox, we used geneexpression profiling (GEP) data and immunohistochemistry to study expression of MHC II and its regulatory genes and to determine their relationship to PMBCL survival. We found that GEP levels correlated between MHC II genes and the transcriptional regulator MHC2TA but not other adjacent genes, implying that transcriptional regulation of MHC II in PMBCL was intact and that MHC II gene deletion was unlikely. MHC II average expression was lower than in certain subtypes of DLBCL; however, only 12% had complete loss of MHC II expression. Poor patient survival in PMBCL correlated with incremental decreases in MHC II expression. Although overall survival was better, survival of the lowest 10% of MHC II expressers was similarly poor in DLBCL and PMBCL. MHC II expression may define a therapeutic target in both these diseases. (Blood. 2006;108:311-318)

13 October 2005 in Blood
Verified
Journal Article
Closed access
PDF file
LRLisa M. Rimsza
Lisa M. Rimsza
RRRobin A Roberts
Robin A Roberts
ECElias Campo
Elias Campo
TGThomas M Grogan
Thomas M Grogan
SBSilvia Bea
Silvia Bea
TMThomas P Miller
Thomas P Miller
Decreased major histocompatibility class II (MHCII) expression is associated with poor survival in diffuse large B-cell lymphoma (DLBCL). Immune-privileged site DLBCL (IP-DLBCL) patients reportedly have frequent large deletions at the MHCII locus whereas the mechanism of decreased expression in non-IP-DLBCL is unknown. Gene expression profiling data were used for correlation analyses between expression levels of MHCII genes with each other and their transcriptional regulator, CIITA. Comparative genomic hybridization (CGH) assessed chromosomal alterations at MHCII-related loci. Finally, a map was created of expression of genes that are telomeric, within, or centromeric to the MHCII locus. Correlation coefficients among MHCII genes ranged from 0.73 to 0.92, whereas those between adjacent and intervening genes were lower (-0.12 to 0.49). Correlations between MHCII and CIITA expression were higher (0.53 to 0.60) than between CIITA and neighboring genes (-0.05 to 0.22). In 23 MHCII- cases, CGH detected 2 losses and 2 gains at MHCII loci. Expression of genes telomeric, within, and centromeric to MHCII loci were near normal in most MHCII- cases. Large deletions of the MHCII locus are uncommon in non-IP-DLBCL, implicating altered transcription as the operative mechanism for decreased expression.

17 July 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JCJennifer R. Chapman
Jennifer R. Chapman
ABAlyssa C. Bouska
Alyssa C. Bouska
WZWeiwei Zhang
Weiwei Zhang
JAJuan Pablo Alderuccio
Juan Pablo Alderuccio
ILIzidore S. Lossos
Izidore S. Lossos
JSJoo Y. Song
Joo Y. Song

1 January 2007 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
LRLisa M. Rimsza
Lisa M. Rimsza
PFPedro Farinha
Pedro Farinha
DFDeborah A. Fuchs
Deborah A. Fuchs
HMHamid Masoudi
Hamid Masoudi
JCJoseph M. Connors
Joseph M. Connors
RGRandy D. Gascoyne
Randy D. Gascoyne
Loss of major histocompatibility class II (MHC class II) molecules on diffuse large B-cell lymphoma (DLBCL) has been associated with poor survival; however, none of these reports analysed a uniformly treated patient cohort. This study was designed to validate one MHC class II antigen, HLA-DR, as a prognostic marker in patients uniformly treated with the MACOP-B regimen. Immunostaining results were correlated with the international prognostic index (IPI) score and overall survival (OS). Of the 97 cases, 82 had interpretable staining. Of these, 52 expressed HLA-DR (median OS, 16.2 years) while 30 were negative (median OS, 4.2 years, P = 0.037). The IPI was also predictive of OS in the study group (P = 0.023). A Cox multivariate model established both IPI (P = 0.031) and HLA-DR (P = 0.04) as independent predictors of OS. This is the first demonstration of the prognostic relevance of HLA-DR in a uniformly treated DLBCL patient group.

22 February 2018 in Haematologica
Verified
Journal Article
Closed access
PDF file
LRLisa M. Rimsza
Lisa M. Rimsza
HLHongli Li
Hongli Li
RBRita M. Braziel
Rita M. Braziel
CSCatherine M. Spier
Catherine M. Spier
DPDaniel O. Persky
Daniel O. Persky
JFJonathan W. Friedberg
Jonathan W. Friedberg